Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

Study acronym: Drug-SNP
StatusActive, Not Recruiting
PhasePhase 2/3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Sep 18, 2026 → Dec 18, 2026
See other at-risk trials from Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor changed: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair to Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair Show 6 more changesShow less
    • Start date: Aug 12, 2025 to Oct 5, 2026
    • Primary endpoints: details revised at 1 of 1 entry
    • Primary completion pushed from Sep 18, 2026 to Dec 18, 2026
    • Study completion pushed from Oct 28, 2026 to Jun 28, 2027
    • Eligibility criteria expanded, about 26 words
    • Study description expanded, about 8 words
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Explore the relationship between drug target topoisomerase I gene single nucleotide polymorphisms and Topotecan therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and Topotecan side-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.
Trial Details
NCT Number NCT07145333
Lead Sponsor Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair
Collaborators: UnitedHealthcare
Conditions
(from sponsor)		 SCLC
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov